COLLABORATIVE DRUG DISCOVERY LICENSE AGREEMENTS (5) FOR BLUEPRINT DATABASE BPN PROJECT SUPPORT.

蓝图数据库 BPN 项目支持的协作药物发现许可协议 (5)。

• 批准号: 8951162
• 金额: $ 1.11万
• 依托单位: COLLABORATIVE DRUG DISCOVERY, INC.
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8951162
• 关键词: Agreement; Basic Science; Biological Assay; Chemical Structure; Chemicals; Collaborations; Contractor; Contracts; Country; Data; Data Analyses; Databases; Human; Individual; Information Systems; Instruction; Licensing; Modeling; Modification; Participant; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacology and Toxicology; Property; Research Personnel; Services; Time; United States National Institutes of Health; Work; analog; drug discovery; high throughput screening; improved; nervous system disorder; programs; research study; small molecule

The NIH is developing a Medicinal Chemistry for Neurotherapeutics Program (MCNP) to generate new optimized drugs leads for nervous system disorders. High-throughput screens and basic research studies have led to the discovery of many small molecule compounds with activity in models of nervous system disorders. Some of these compounds have the potential to be transformed into drugs for human use, with chemical modifications to improve their potency and pharmacological properties. The MCNP will support collaborations between a contracted medicinal chemistry facility, and researchers (Contributors) with bioactive small molecule compounds and bioactivity assays to develop optimized drug leads.

NIH正在开发神经疗法计划（MCNP）的药物化学，以生成新的优化药物铅来治疗神经系统疾病。高通量筛选和基础研究导致发现了许多小分子化合物，在神经系统疾病模型中具有活性。其中一些化合物有可能转化为人类使用的药物，并具有化学修饰以提高其效力和药理特性。 MCNP将支持合同的药物化学设施与具有生物活性小分子化合物和生物活性测定的研究人员（贡献者）之间的合作，以开发优化的药物铅。